Catania Plus/Catania Max Dosage/Direction for Use

Recommended Administration: Once a day, take Dapagliflozin and Metformin HCl (As Extended Release) Tablets orally in the morning along with some food.
Never chew, cut, or crush Dapagliflozin and Metformin HCl (As Extended Release) Tablets; instead, swallow them whole.
Recommended Dosage: Determine the patient's starting Dapagliflozin and Metformin HCl (As Extended Release) Tablets dosage depending on their current treatment plan. Before beginning Dapagliflozin and Metformin HCl (As Extended Release) Tablets, patients receiving an evening dosage of metformin HCl extended-release should forgo their previous dose.
For patients 10 years of age and older who are not currently taking dapagliflozin, a starting dose of 5 mg once daily is advised in order to enhance glycemic control.
The recommended dosage of dapagliflozin for individuals with heart failure and chronic renal disease is 10 mg once a day.
The maximum recommended daily dosage of 10 mg dapagliflozin and 2,000 mg metformin HCl extended-release maybe exceeded, however dosage maybe changed based on effectiveness and tolerability.
Recommended Dosage in Patients with Renal Impairment: Patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m² or higher do not require a dosage adjustment for Dapagliflozin and Metformin HCl (As Extended Release) Tablets.
For patients with an eGFR between 30 and 45 mL/min/1.73 m², starting Dapagliflozin and Metformin HCl (As Extended Release) Tablets is not advised. If eGFR consistently drops below this threshold, weigh the advantages and disadvantages of continuing treatment.
Patients with an eGFR of less than 45 mL/min/1.73 m² are unlikely to benefit from dapagliflozin in terms of improved glycemic control.
It is not advised to start metformin HCl in patients whose eGFR is less than 45 mL/min/1.73 m².
Patients with end-stage renal disease, dialysis, or an eGFR below 30 mL/min/1.73 m² should not take dapagliflozin and metformin HCl (as extended release) tablets because of the metformin HCl component.
Discontinuation for Iodinated Contrast Imaging Procedures: Patients with a history of liver disease, alcoholism, or heart failure, as well as those who will receive intra-arterial iodinated contrast, should stop taking Dapagliflozin and Metformin HCl (As Extended Release) Tablets at the time of or before an iodinated contrast imaging procedure. 48 hours following the imaging procedure, reevaluate eGFR; if renal function is stable, resume taking Dapagliflozin and Metformin HCl (As Extended Release) tablets.
Temporary Interruption for Surgery: If at all possible, avoid taking Dapagliflozin and Metformin HCl (As Extended Release) Tablets for at least three days before undergoing major surgery or extended fasting procedures. Once the patient is clinically stable and has resumed oral intake, start taking Dapagliflozin and Metformin HCl (As Extended Release) tablets again.